Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.

Strocchi E, Fornari F, Minguzzi M, Gramantieri L, Milazzo M, Rebuttini V, Breviglieri S, Camaggi CM, Locatelli E, Bolondi L, Comes-Franchini M.

Eur J Med Chem. 2012 Feb;48:391-401. doi: 10.1016/j.ejmech.2011.12.031. Epub 2011 Dec 29.

PMID:
22227043
2.

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.

Lv PC, Li DD, Li QS, Lu X, Xiao ZP, Zhu HL.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5374-7. doi: 10.1016/j.bmcl.2011.07.010. Epub 2011 Jul 14.

PMID:
21802290
3.

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG.

J Med Chem. 2010 Mar 11;53(5):2171-87. doi: 10.1021/jm901710h.

PMID:
20141146
4.

Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.

Liu JJ, Daniewski I, Ding Q, Higgins B, Ju G, Kolinsky K, Konzelmann F, Lukacs C, Pizzolato G, Rossman P, Swain A, Thakkar K, Wei CC, Miklowski D, Yang H, Yin X, Wovkulich PM.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):5984-7. doi: 10.1016/j.bmcl.2010.08.079. Epub 2010 Aug 21.

PMID:
20832307
5.

New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.

Choi WK, El-Gamal MI, Choi HS, Baek D, Oh CH.

Eur J Med Chem. 2011 Dec;46(12):5754-62. doi: 10.1016/j.ejmech.2011.08.013. Epub 2011 Aug 12.

PMID:
22014559
6.

Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.

Wang SF, Zhu YL, Zhu PT, Makawana JA, Zhang YL, Zhao MY, Lv PC, Zhu HL.

Bioorg Med Chem. 2014 Nov 1;22(21):6201-8. doi: 10.1016/j.bmc.2014.08.029. Epub 2014 Sep 6.

PMID:
25267006
7.

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Li X, Lu X, Xing M, Yang XH, Zhao TT, Gong HB, Zhu HL.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3589-93. doi: 10.1016/j.bmcl.2012.04.066. Epub 2012 Apr 21.

PMID:
22572580
8.

Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.

Lin R, Connolly PJ, Lu Y, Chiu G, Li S, Yu Y, Huang S, Li X, Emanuel SL, Middleton SA, Gruninger RH, Adams M, Fuentes-Pesquera AR, Greenberger LM.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4297-302. Epub 2007 May 16.

PMID:
17532631
9.

Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-╬▓ type 1 receptor kinase inhibitors.

Jin CH, Sreenu D, Krishnaiah M, Subrahmanyam VB, Rao KS, Nagendra Mohan AV, Park CY, Son JY, Son DH, Park HJ, Sheen YY, Kim DK.

Eur J Med Chem. 2011 Sep;46(9):3917-25. doi: 10.1016/j.ejmech.2011.05.063. Epub 2011 Jun 22.

PMID:
21696866
10.

Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.

El-Deeb IM, Lee SH.

Bioorg Med Chem. 2010 Jun 1;18(11):3961-73. doi: 10.1016/j.bmc.2010.04.029. Epub 2010 May 14.

PMID:
20472440
11.

Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.

Liu JJ, Zhang H, Sun J, Wang ZC, Yang YS, Li DD, Zhang F, Gong HB, Zhu HL.

Bioorg Med Chem. 2012 Oct 15;20(20):6089-96. doi: 10.1016/j.bmc.2012.08.020. Epub 2012 Aug 25.

PMID:
22985957
12.

Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents.

Liu XH, Ruan BF, Liu JX, Song BA, Jing LH, Li J, Yang Y, Zhu HL, Qi XB.

Bioorg Med Chem Lett. 2011 May 15;21(10):2916-20. doi: 10.1016/j.bmcl.2011.03.066. Epub 2011 Mar 23.

PMID:
21486698
13.

Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.

Liu K, Lu X, Zhang HJ, Sun J, Zhu HL.

Eur J Med Chem. 2012 Jan;47(1):473-8. doi: 10.1016/j.ejmech.2011.11.015. Epub 2011 Nov 18.

PMID:
22119130
14.

Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.

Yang XH, Xiang L, Li X, Zhao TT, Zhang H, Zhou WP, Wang XM, Gong HB, Zhu HL.

Bioorg Med Chem. 2012 May 1;20(9):2789-95. doi: 10.1016/j.bmc.2012.03.040. Epub 2012 Mar 24.

PMID:
22503364
15.

Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.

Bandgar BP, Totre JV, Gawande SS, Khobragade CN, Warangkar SC, Kadam PD.

Bioorg Med Chem. 2010 Aug 15;18(16):6149-55. doi: 10.1016/j.bmc.2010.06.046. Epub 2010 Jun 19.

PMID:
20638287
16.

Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.

Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4720-3. doi: 10.1016/j.bmcl.2009.06.066. Epub 2009 Jun 21.

PMID:
19596575
17.

Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.

Hawash MM, Kahraman DC, Eren F, Cetin Atalay R, Baytas SN.

Eur J Med Chem. 2017 Mar 31;129:12-26. doi: 10.1016/j.ejmech.2017.02.002. Epub 2017 Feb 10.

PMID:
28219046
18.

Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.

Ho HK, Chua BT, Wong W, Lim KS, Teo V, Ong HT, Chen X, Zhang W, Hui KM, Go ML, Ullrich A.

Mol Oncol. 2014 Oct;8(7):1266-77. doi: 10.1016/j.molonc.2014.04.008. Epub 2014 May 2.

19.

Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity.

Balbi A, Anzaldi M, Macci├▓ C, Aiello C, Mazzei M, Gangemi R, Castagnola P, Miele M, Rosano C, Viale M.

Eur J Med Chem. 2011 Nov;46(11):5293-309. doi: 10.1016/j.ejmech.2011.08.014. Epub 2011 Aug 31.

PMID:
21920636
20.

Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.

Abreu RM, Ferreira IC, Calhelha RC, Lima RT, Vasconcelos MH, Adega F, Chaves R, Queiroz MJ.

Eur J Med Chem. 2011 Dec;46(12):5800-6. doi: 10.1016/j.ejmech.2011.09.029. Epub 2011 Oct 6.

PMID:
22014996

Supplemental Content

Support Center